These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35358291)

  • 1. Clinical effectiveness of beta-lactams versus fluoroquinolones as empirical therapy in patients with diabetes mellitus hospitalized for urinary tract infections: A retrospective cohort study.
    Tang YH; Lu PL; Huang HY; Lin YC
    PLoS One; 2022; 17(3):e0266416. PubMed ID: 35358291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral beta-lactam step down in bacteremic E. coli urinary tract infections.
    Saad S; Mina N; Lee C; Afra K
    BMC Infect Dis; 2020 Oct; 20(1):785. PubMed ID: 33087051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens.
    Chen YH; Ko WC; Hsueh PR
    Eur J Clin Microbiol Infect Dis; 2012 Aug; 31(8):1699-704. PubMed ID: 22052606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High fluoroquinolone MIC is associated with fluoroquinolone treatment failure in urinary tract infections caused by fluoroquinolone susceptible Escherichia coli.
    Rattanaumpawan P; Nachamkin I; Bilker WB; Roy JA; Metlay JP; Zaoutis TE; Lautenbach E;
    Ann Clin Microbiol Antimicrob; 2017 Apr; 16(1):25. PubMed ID: 28390438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefazolin versus fluoroquinolones for the treatment of community-acquired urinary tract infections in hospitalized patients.
    Uppala A; King EA; Patel D
    Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1533-1538. PubMed ID: 31114972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating outcomes associated with revised fluoroquinolone breakpoints for Enterobacterales urinary tract infections: A retrospective cohort study.
    Benavides TM; Aden JK; Giancola SE
    Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):741-749. PubMed ID: 35224677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
    Lu PL; Liu YC; Toh HS; Lee YL; Liu YM; Ho CM; Huang CC; Liu CE; Ko WC; Wang JH; Tang HJ; Yu KW; Chen YS; Chuang YC; Xu Y; Ni Y; Chen YH; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S37-43. PubMed ID: 22749057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the 2014 Clinical and Laboratory Standards Institute urine-specific breakpoints on cefazolin susceptibility rates at a community teaching hospital.
    Chastain DB; Ngando I; Bland CM; Franco-Paredes C; Hawkins WA
    Ann Clin Microbiol Antimicrob; 2017 May; 16(1):43. PubMed ID: 28558707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empirical fluoroquinolones versus broad-spectrum beta-lactams for Gram-negative bloodstream infections in the absence of antimicrobial resistance risk factors.
    Al-Hasan MN; Gould AP; Drennan C; Hill O; Justo JA; Kohn J; Bookstaver PB
    J Glob Antimicrob Resist; 2020 Sep; 22():87-93. PubMed ID: 31887412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective review of ceftriaxone versus levofloxacin for treatment of E. coli urinary tract infections.
    Wang SS; Ratliff PD; Judd WR
    Int J Clin Pharm; 2018 Feb; 40(1):143-149. PubMed ID: 29147962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli.
    Gagliotti C; Buttazzi R; Sforza S; Moro ML;
    J Infect; 2008 Sep; 57(3):179-84. PubMed ID: 18707763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams.
    Kariuki S; Revathi G; Corkill J; Kiiru J; Mwituria J; Mirza N; Hart CA
    J Infect Dev Ctries; 2007 Dec; 1(3):257-62. PubMed ID: 19734602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?
    Wu PF; Lin YT; Wang FD; Yang TC; Fung CP
    Infection; 2018 Jun; 46(3):365-373. PubMed ID: 29556979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study.
    Daneman N; Chateau D; Dahl M; Zhang J; Fisher A; Sketris IS; Quail J; Marra F; Ernst P; Bugden S;
    Clin Microbiol Infect; 2020 May; 26(5):613-618. PubMed ID: 31655215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of recurrent complicated urinary tract infections in children with vesicoureteral reflux.
    Wu TH; Huang FL; Fu LS; Chou CM; Chien YL; Huang CM; Lin CF; Chen PY
    J Microbiol Immunol Infect; 2016 Oct; 49(5):717-722. PubMed ID: 25442872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiology and Drug Resistance of Pathogens in Patients Hospitalized at the Nephrology Department in the South of Poland.
    Michno M; Sydor A; Wałaszek M; Sułowicz W
    Pol J Microbiol; 2018; 67(4):517-524. PubMed ID: 30550238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral β-Lactam Antibiotics vs Fluoroquinolones or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Enterobacterales Bacteremia From a Urine Source.
    Sutton JD; Stevens VW; Chang NN; Khader K; Timbrook TT; Spivak ES
    JAMA Netw Open; 2020 Oct; 3(10):e2020166. PubMed ID: 33030555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluoroquinolone and Third-Generation-Cephalosporin Resistance among Hospitalized Patients with Urinary Tract Infections Due to Escherichia coli: Do Rates Vary by Hospital Characteristics and Geographic Region?
    Bidell MR; Palchak M; Mohr J; Lodise TP
    Antimicrob Agents Chemother; 2016 May; 60(5):3170-3. PubMed ID: 26926640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.